Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 181.00
+3.00 (1.69%)
Last updated: Dec 1, 2025, 8:19 AM CET
Ascendis Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 646.55 | 363.64 | 266.72 | 51.17 | 7.78 | 6.95 | Upgrade | |
Revenue Growth (YoY) | 97.46% | 36.34% | 421.20% | 557.93% | 11.87% | -48.02% | Upgrade |
Cost of Revenue | 85.34 | 44.26 | 44.4 | 12.14 | 3.52 | - | Upgrade |
Gross Profit | 561.21 | 319.38 | 222.32 | 39.04 | 4.26 | 6.95 | Upgrade |
Selling, General & Admin | 398.77 | 291.14 | 264.41 | 221.23 | 160.18 | 76.67 | Upgrade |
Research & Development | 300.71 | 307 | 413.45 | 379.62 | 295.87 | 260.9 | Upgrade |
Operating Expenses | 699.48 | 598.15 | 677.86 | 600.85 | 456.05 | 337.57 | Upgrade |
Operating Income | -138.28 | -278.76 | -455.54 | -561.81 | -451.79 | -330.62 | Upgrade |
Interest Expense | -139.72 | -65.5 | -44.07 | -30.68 | -3.91 | -1.92 | Upgrade |
Interest & Investment Income | 75.05 | 14.36 | 16.86 | 7.43 | 0.69 | 1.81 | Upgrade |
Earnings From Equity Investments | 10.41 | -20.06 | -18.4 | -17.7 | 12.04 | -9.52 | Upgrade |
Currency Exchange Gain (Loss) | -27.15 | -27.15 | 12.35 | 40.43 | 59.03 | -78.92 | Upgrade |
Other Non Operating Income (Expenses) | 3.87 | 3.87 | 14.65 | -15.48 | - | - | Upgrade |
Pretax Income | -223.33 | -373.24 | -474.14 | -577.82 | -383.94 | -419.17 | Upgrade |
Income Tax Expense | 9.61 | 4.84 | 7.3 | 5.38 | -0.37 | -0.22 | Upgrade |
Net Income | -232.94 | -378.08 | -481.45 | -583.19 | -383.58 | -418.96 | Upgrade |
Net Income to Common | -232.94 | -378.08 | -481.45 | -583.19 | -383.58 | -418.96 | Upgrade |
Shares Outstanding (Basic) | 60 | 58 | 56 | 56 | 55 | 51 | Upgrade |
Shares Outstanding (Diluted) | 60 | 58 | 56 | 56 | 55 | 51 | Upgrade |
Shares Change (YoY) | 5.56% | 2.85% | 0.38% | 2.37% | 8.21% | 8.84% | Upgrade |
EPS (Basic) | -3.87 | -6.53 | -8.55 | -10.40 | -7.00 | -8.28 | Upgrade |
EPS (Diluted) | -3.87 | -6.53 | -8.55 | -10.40 | -7.00 | -8.28 | Upgrade |
Free Cash Flow | -112.15 | -307.62 | -469.8 | -510.19 | -441.35 | -291.41 | Upgrade |
Free Cash Flow Per Share | -1.86 | -5.31 | -8.35 | -9.10 | -8.06 | -5.76 | Upgrade |
Gross Margin | 86.80% | 87.83% | 83.36% | 76.28% | 54.71% | 100.00% | Upgrade |
Operating Margin | -21.39% | -76.66% | -170.80% | -1097.85% | -5808.59% | -4755.07% | Upgrade |
Profit Margin | -36.03% | -103.97% | -180.51% | -1139.63% | -4931.56% | -6025.53% | Upgrade |
Free Cash Flow Margin | -17.35% | -84.60% | -176.14% | -996.97% | -5674.38% | -4191.11% | Upgrade |
EBITDA | -133.71 | -273.83 | -448.99 | -544.3 | -436.85 | -321.17 | Upgrade |
EBITDA Margin | -20.68% | -75.30% | -168.34% | - | - | - | Upgrade |
D&A For EBITDA | 4.57 | 4.94 | 6.55 | 17.51 | 14.95 | 9.45 | Upgrade |
EBIT | -138.28 | -278.76 | -455.54 | -561.81 | -451.79 | -330.62 | Upgrade |
EBIT Margin | -21.39% | -76.66% | -170.80% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.